BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial
The safety profile was described as manageable, though not without notable toxicities
The safety profile was described as manageable, though not without notable toxicities
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Positive opinions based on significant survival benefit
Subscribe To Our Newsletter & Stay Updated